^
    Back
    Association details:
    Biomarker:IRF2 overexpression
    Cancer:Colorectal Cancer
    Drug Class:PD-L1 inhibitor
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    New
    Source:
    Cancer Cell
    Title:

    KRAS-IRF2 axis drives immune suppression and immune therapy resistance in colorectal cancer

    Excerpt:
    IRF2 Expression Predicts anti-PD-1 Therapy Responses in CRC...In this small cohort, higher IRF2 expression correlated positively with better response to anti-PD-1 therapy.
    DOI:
    10.1016/j.ccell.2019.02.008